Manuscripts and Publications

Filters: Keyword is Anti-HIV Agents  [Clear All Filters]
2018
Gamarel KE, Westfall AO, Lally MA, Hosek S, Wilson CM.  2018.  Tobacco Use and Sustained Viral Suppression in Youth Living with HIV.. AIDS Behav. 22(6):2018-2025.
2017
Havens PL, Stephensen CB, Van Loan MD, Schuster GU, Woodhouse LR, Flynn PM, Gordon CM, Pan CG, Rutledge B, Liu N et al..  2017.  Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure Prophylaxis.. Clin Infect Dis. 64(3):317-325.
Mullins TLKowalczy, Zimet G, Lally M, Xu J, Thornton S, Kahn JA.  2017.  HIV Care Providers' Intentions to Prescribe and Actual Prescription of Pre-Exposure Prophylaxis to At-Risk Adolescents and Adults.. AIDS Patient Care STDS. 31(12):504-516.
Hosek SG, Rudy B, Landovitz R, Kapogiannis B, Siberry G, Rutledge B, Liu N, Brothers J, Mulligan K, Zimet G et al..  2017.  An HIV Preexposure Prophylaxis Demonstration Project and Safety Study for Young MSM.. J Acquir Immune Defic Syndr. 74(1):21-29.
Hosek SG, Landovitz RJ, Kapogiannis B, Siberry GK, Rudy B, Rutledge B, Liu N, D Harris R, Mulligan K, Zimet G et al..  2017.  Safety and Feasibility of Antiretroviral Preexposure Prophylaxis for Adolescent Men Who Have Sex With Men Aged 15 to 17 Years in the United States.. JAMA Pediatr. 171(11):1063-1071.
Philbin MM, Tanner AE, Duval A, Ellen JM, Kapogiannis B, J Fortenberry D.  2017.  Understanding Care Linkage and Engagement Across 15 Adolescent Clinics: Provider Perspectives and Implications for Newly HIV-Infected Youth.. AIDS Educ Prev. 29(2):93-104.
2016
Mullins TLKowalczy, Zimet G, Lally M, Kahn JA.  2016.  Adolescent Human Immunodeficiency Virus Care Providers' Attitudes Toward the Use of Oral Pre-Exposure Prophylaxis in Youth.. AIDS Patient Care STDS. 30(7):339-48.
Nichols SL, Bethel J, Kapogiannis BG, Li T, Woods SP, E Patton D, Ren W, Thornton SE, Major-Wilson HO, Puga AM et al..  2016.  Antiretroviral treatment initiation does not differentially alter neurocognitive functioning over time in youth with behaviorally acquired HIV.. J Neurovirol. 22(2):218-30.
Dowshen N, Matone M, Luan X, Lee S, Belzer M, Fernandez MIsabel, Rubin D.  2016.  Behavioral and Health Outcomes for HIV+ Young Transgender Women (YTW) Linked To and Engaged in Medical Care.. LGBT Health. 3(2):162-7.
Castillo-Mancilla J, Seifert S, Campbell K, Coleman S, McAllister K, Zheng J-H, Gardner EM, Liu A, Glidden DV, Grant R et al..  2016.  Emtricitabine-Triphosphate in Dried Blood Spots as a Marker of Recent Dosing.. Antimicrob Agents Chemother. 60(11):6692-6697.
Gross IMoses, Hosek S, Richards MHeather, M Fernández I.  2016.  Predictors and Profiles of Antiretroviral Therapy Adherence Among African American Adolescents and Young Adult Males Living with HIV.. AIDS Patient Care STDS. 30(7):324-38.
Tanner AE, Philbin MM, Duval A, Ellen J, Kapogiannis B, J Fortenberry D.  2016.  Transitioning HIV-Positive Adolescents to Adult Care: Lessons Learned From Twelve Adolescent Medicine Clinics.. J Pediatr Nurs. 31(5):537-43.
2015
Belzer ME, MacDonell KKolmodin, Clark LF, Huang J, Olson J, Kahana SY, Naar S, Sarr M, Thornton S.  2015.  Acceptability and Feasibility of a Cell Phone Support Intervention for Youth Living with HIV with Nonadherence to Antiretroviral Therapy.. AIDS Patient Care STDS. 29(6):338-45.
Havens PL, Hazra R.  2015.  Commentary: The place of tenofovir disoproxil fumarate in pediatric antiretroviral therapy.. Pediatr Infect Dis J. 34(4):406-8.
Rudy BJ, Kapogiannis BG, Worrell C, Squires K, Bethel J, Li S, Wilson CM, Agwu A, Emmanuel P, Price G et al..  2015.  Immune Reconstitution but Persistent Activation After 48 Weeks of Antiretroviral Therapy in Youth With Pre-Therapy CD4 >350 in ATN 061.. J Acquir Immune Defic Syndr. 69(1):52-60.
Brown LK, Whiteley L, Harper GW, Nichols S, Nieves A.  2015.  Psychological symptoms among 2032 youth living with HIV: a multisite study.. AIDS Patient Care STDS. 29(4):212-9.
2014
Belzer ME, Naar-King S, Olson J, Sarr M, Thornton S, Kahana SY, Gaur AH, Clark LF.  2014.  The use of cell phone support for non-adherent HIV-infected youth and young adults: an initial randomized and controlled intervention trial.. AIDS Behav. 18(4):686-96.
Havens PL, Hazra R, Stephensen CB, Kiser JJ, Flynn PM, Wilson CM, Rutledge B, Bethel J, Pan CG, Woodhouse LR et al..  2014.  Vitamin D3 supplementation increases fibroblast growth factor-23 in HIV-infected youths treated with tenofovir disoproxil fumarate.. Antivir Ther. 19(6):613-8.
2013
Havens PL, Kiser JJ, Stephensen CB, Hazra R, Flynn PM, Wilson CM, Rutledge B, Bethel J, Pan CG, Woodhouse LR et al..  2013.  Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency? Antimicrob Agents Chemother. 57(11):5619-28.
MacDonell K, Naar-King S, Huszti H, Belzer M.  2013.  Barriers to medication adherence in behaviorally and perinatally infected youth living with HIV.. AIDS Behav. 17(1):86-93.
2012
Martinez J, Harper G, Carleton RA, Hosek S, Bojan K, Clum G, Glum G, Ellen J.  2012.  The impact of stigma on medication adherence among HIV-positive adolescent and young adult females and the moderating effects of coping and satisfaction with health care.. AIDS Patient Care STDS. 26(2):108-15.
Havens PL, Stephensen CB, Hazra R, Flynn PM, Wilson CM, Rutledge B, Bethel J, Pan CG, Woodhouse LR, Van Loan MD et al..  2012.  Vitamin D3 decreases parathyroid hormone in HIV-infected youth being treated with tenofovir: a randomized, placebo-controlled trial.. Clin Infect Dis. 54(7):1013-25.
2009
Naar-King S, Parsons JT, Murphy DA, Chen X, D Harris R, Belzer ME.  2009.  Improving health outcomes for youth living with the human immunodeficiency virus: a multisite randomized trial of a motivational intervention targeting multiple risk behaviors.. Arch Pediatr Adolesc Med. 163(12):1092-8.
Rudy BJ, Sleasman J, Kapogiannis B, Wilson CM, Bethel J, Serchuck L, Ahmad S, Cunningham CK.  2009.  Short-cycle therapy in adolescents after continuous therapy with established viral suppression: the impact on viral load suppression.. AIDS Res Hum Retroviruses. 25(6):555-61.
2008
Kiser JJ, Fletcher CV, Flynn PM, Cunningham CK, Wilson CM, Kapogiannis BG, Major-Wilson H, Viani RM, Liu NX, Muenz LR et al..  2008.  Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.. Antimicrob Agents Chemother. 52(2):631-7.
2006
Viani RM, Peralta L, Aldrovandi G, Kapogiannis BG, Mitchell R, Spector SA, Lie YS, Weidler JM, Bates MP, Liu N et al..  2006.  Prevalence of primary HIV-1 drug resistance among recently infected adolescents: a multicenter adolescent medicine trials network for HIV/AIDS interventions study.. J Infect Dis. 194(11):1505-9.